title: Assessment of structural and functıonal vısual outcomes ın relapsıng remıttıng multıple sclerosıs wıth vısual evoked potentıals and optıcal coherence tomography.
abstract: The purpose of this study is to consider the clinical utility of optical coherence tomography (OCT) and find a correlation with VEP. Effects of different disease modifying treatments (DMT) were further evaluated by measuring OCT parameters and whether a correlation exists between the RNFL thickness, disease duration and expanded disability status scale (EDSS) were also assessed. 13 patients were on interferon beta-1a (IFN), 14 patients were receiving glatiramer acetate (GA), 19 patients were not being treated with any DMT and 21 healthy controls were included the study. During OCT examination, retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) thickness was found to be lower in all MS groups but macular volume (MV) was lower only in GA group than controls. Although, P100 latencies were longer than controls in all MS groups, there was no statistically significant difference between IFN and w/o DMT groups. Patients with ON history, P100 latencies were found significantly longer than those without ON. VEP amplitudes were found lower with ON history patients than those without ON, however this was not statistically significant. EDSS strongly correlated with P100 latency, RNLF, GCC but no correlation was observed with VEP amplitude and MV. Our results show that RNFL, GCC and MV were all decreased in MS patients with or without DMT comparing to controls and it is more prominent in eyes with ON. Further follow-up studies are warranted to understand the pathophysiology of CNS axonal degeneration and involvement of optic nerves.
authors.affiliation: Bakirkoy Education and Research Hospital, Ophthalmology Department, Istanbul, Turkey.
authors.forename: Betul
authors.initials: B
authors.lastname: Tugcu
authors.forename: Aysun
authors.initials: A
authors.lastname: Soysal
authors.forename: Murat
authors.initials: M
authors.lastname: Kılıc
authors.forename: Burcu
authors.initials: B
authors.lastname: Yuksel
authors.forename: Nılufer
authors.initials: N
authors.lastname: Kale
authors.forename: Ulvıye
authors.initials: U
authors.lastname: Yıgıt
authors.forename: Baki
authors.initials: B
authors.lastname: Arpaci
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D000704:Analysis of Variance; D004569:Electroencephalography; D005074:Evoked Potentials, Visual / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications* / Q000188:drug therapy; D010775:Photic Stimulation; D041623:Tomography, Optical Coherence; D014786:Vision Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology*
chemical_list: D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a
keywords: Multiple sclerosis; OCT; Optic coherence tomography; RNFL; VEP; Visual evoked potentials